Skip to content

Study · Case report or series · n = 1 · 2024

2 results

Semaglutide-induced Hyperemesis Gravidarum.

Okeke IG, Camarda AR, Okeke R, Chaughtai S

JCEM case reports18 Jan 2024Cited by 8 (Europe PMC)

PMID38249445 (opens in a new tab)PMCIDPMC10798820 (opens in a new tab)DOI10.1210/jcemcr/luad167 (opens in a new tab)PepBankPUB-38249445
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In one woman at 7 weeks of pregnancy, a high subcutaneous dose of semaglutide (2 mg) was followed by extreme nausea, vomiting, abdominal cramping and anorexia, reported as semaglutide-induced hyperemesis gravidarum.

    In plain wordsOne pregnant woman who took a high dose of semaglutide had severe nausea and vomiting that the authors linked to the drug.

    Peptide
    Semaglutide
    Outcome
    Not applicableHyperemesis gravidarum after semaglutide
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    2 mg · subcutaneousAs given in this study (human).

    Measurements

    Semaglutide dose
    2 mg
    subcutaneous

    Source sentences

    Summary
    Here we present the first reported case of hyperemesis gravidarum (HG) induced by semaglutide.
    2 context sentences
    Summary · context
    Our patient presented at 7 weeks' gestational age with 4 days of extreme nausea, vomiting, abdominal cramping, and anorexia, symptoms that she did not experience in prior pregnancies.
    Summary · context
    She later informed the medical team of her use of a high dose of subcutaneous semaglutide (2 mg) the day of symptom onset before discovering her pregnancy; semaglutide was obtained online without clinicians' guidance.
  2. 02HumanCase report or seriesSafety outcome

    In the same patient, symptoms resolved 6 days after taking semaglutide, which closely coincides with its half-life.

    In plain wordsIn this one patient, symptoms went away 6 days after taking semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableResolution of symptoms after semaglutide
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    2 mg · subcutaneousAs given in this study (human).

    Measurements

    Time to symptom resolution
    6 days
    after semaglutide dose

    Source sentences

    Summary
    Her symptoms resolved 6 days after taking semaglutide, which closely coincides with semaglutide's half-life.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.